Recent studies have centered on the convergence of glucagon-like peptide-1|GIP|glucagon receptor stimulant therapies and dopamine neurotransmission. While GCGR activators are commonly employed for addressing type 2 diabetes, their potential effects on reward circuits, specifically influenced by dopamine systems, are attracting significant interest.